X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2024-07-24 | WGS | Genedx Holdings Corp. | Opko Health, Inc. | 10% | S - Sale | $33.78 | -135,000 | 3,123,403 | -4% | -$4,560,363 | |||||
2024-07-02 | KZR | Kezar Life Sciences, Inc. | Schiller Mark C. | GC | S - Sale | $0.58 | -6,688 | 33,007 | -17% | -$3,879 | ||||||
| DM | 2024-07-24 | PEPG | Pepgen Inc. | Mellion Michelle L | Chief Medical Officer | S - Sale+OE | $18.06 | -7,772 | 0 | -100% | -$140,360 | |||||
2024-07-25 | CRNX | Crinetics Pharmaceuticals, Inc. | Betz Stephen F. | Chief Scientific Officer | S - Sale | $53.43 | -3,000 | 75,611 | -4% | -$160,290 | ||||||
| D | 2024-07-24 | PTGX | Protagonist Therapeutics, Inc | Waddill William D. | Dir | S - Sale+OE | $40.00 | -8,000 | 12,000 | -40% | -$320,000 | |||||
| D | 2024-07-25 | CRNX | Crinetics Pharmaceuticals, Inc. | Wilson Marc | CFO | S - Sale+OE | $53.88 | -19,056 | 111,092 | -15% | -$1,026,737 | |||||
| M | 2024-07-24 | TNGX | Tango Therapeutics, Inc. | Third Rock Ventures Iv, L.P. | 10% | S - Sale | $9.83 | -300,599 | 17,771,475 | -2% | -$2,955,931 | |||||
2024-07-26 | ANIX | Anixa Biosciences Inc | Baskies Arnold M | Dir | P - Purchase | $3.09 | +5,000 | 115,000 | +5% | +$15,450 | ||||||
| DM | 2024-07-23 | AKRO | Akero Therapeutics, Inc. | White William Richard | CFO | S - Sale+OE | $27.07 | -161,855 | 41,791 | -79% | -$4,381,867 | |||||
| D | 2024-07-23 | KNSA | Kiniksa Pharmaceuticals International, Plc | Patel Sanj K | COB, CEO | S - Sale+OE | $25.65 | -136,124 | 172,807 | -44% | -$3,491,947 | |||||
| D | 2024-07-23 | KNSA | Kiniksa Pharmaceuticals International, Plc | Ragosa Mark | CFO | S - Sale+OE | $24.79 | -24,248 | 19,253 | -56% | -$601,108 | |||||
| D | 2024-07-23 | KNSA | Kiniksa Pharmaceuticals International, Plc | Paolini John F. | CHIEF MEDICAL OFFICER | S - Sale+OE | $26.32 | -22,000 | 47,803 | -32% | -$578,966 | |||||
| DM | 2024-07-23 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $334.69 | -7,200 | 646,231 | -1% | -$2,409,782 | |||||
2024-07-24 | VRTX | Vertex Pharmaceuticals Inc / Ma | Bozic Carmen | EVP, CMO | S - Sale | $488.46 | -2,280 | 25,539 | -8% | -$1,113,689 | ||||||
2024-07-23 | SGMT | Sagimet Biosciences Inc. | Kemble George | Exec COB | S - Sale | $3.17 | -23,625 | 118,693 | -17% | -$74,830 | ||||||
| M | 2024-07-22 | TNGX | Tango Therapeutics, Inc. | Third Rock Ventures Iv, L.P. | 10% | S - Sale | $9.78 | -387,740 | 18,072,074 | -2% | -$3,793,446 | |||||
2024-07-22 | VRTX | Vertex Pharmaceuticals Inc / Ma | Kewalramani Reshma | CEO, Pres | S - Sale | $497.00 | -15,202 | 106,172 | -13% | -$7,555,394 | ||||||
2024-07-22 | RCKT | Rocket Pharmaceuticals, Inc. | Militello John | See Remarks | S - Sale | $23.02 | -812 | 52,515 | -2% | -$18,688 | ||||||
2024-07-23 | GLSI | Greenwich Lifesciences, Inc. | Patel Snehal | CEO, CFO, 10% | P - Purchase | $15.89 | +1,500 | 5,527,102 | 0% | +$23,835 | ||||||
| M | 2024-07-22 | VRCA | Verrica Pharmaceuticals Inc. | White Ted | Pres, CEO | S - Sale | $7.06 | -32,623 | 249,967 | -12% | -$230,306 | |||||
| M | 2024-07-22 | VRCA | Verrica Pharmaceuticals Inc. | Bonaccorso Joe | Chief Commercial Officer | S - Sale | $7.06 | -25,576 | 106,816 | -19% | -$180,557 | |||||
| M | 2024-07-22 | VRCA | Verrica Pharmaceuticals Inc. | Goldenberg Gary | Chief Medical Officer | S - Sale | $7.06 | -18,507 | 107,750 | -15% | -$130,653 | |||||
| M | 2024-07-22 | VRCA | Verrica Pharmaceuticals Inc. | Hayes Christopher G. | GC | S - Sale | $7.06 | -21,740 | 141,486 | -13% | -$153,477 | |||||
| M | 2024-07-19 | WGS | Genedx Holdings Corp. | Opko Health, Inc. | 10% | S - Sale | $32.98 | -150,000 | 3,258,403 | -4% | -$4,946,935 | |||||
| M | 2024-07-19 | ELYM | Eliem Therapeutics, Inc. | Morisset Valerie | EVP, R, D, CSO | S - Sale | $7.65 | -129,206 | 31,317 | -80% | -$988,495 | |||||
| D | 2024-07-23 | CYTK | Cytokinetics Inc | Malik Fady Ibraham | EVP Research, Development | S - Sale+OE | $57.02 | -7,300 | 129,004 | -5% | -$416,246 | |||||
| DM | 2024-07-19 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $330.45 | -7,200 | 646,231 | -1% | -$2,379,244 | |||||
| D | 2024-07-19 | RNA | Avidity Biosciences, Inc. | Levin Arthur A | Dir | S - Sale+OE | $45.01 | -5,000 | 168,702 | -3% | -$225,069 | |||||
2024-07-19 | SGMT | Sagimet Biosciences Inc. | Martins Eduardo Bruno | Chief Medical Officer | S - Sale | $3.10 | -8,357 | 81,213 | -9% | -$25,910 | ||||||
2024-07-19 | SGMT | Sagimet Biosciences Inc. | Rozek Elizabeth | GC, CCO | S - Sale | $3.10 | -10,914 | 160,506 | -6% | -$33,830 | ||||||
2024-07-19 | SGMT | Sagimet Biosciences Inc. | Kemble George | Exec COB | S - Sale | $3.10 | -14,062 | 142,318 | -9% | -$43,605 | ||||||
2024-07-23 | DERM | Journey Medical Corp | Benesch Joseph | CFO | S - Sale | $5.40 | -4,055 | 56,655 | -7% | -$21,897 | ||||||
| A | 2024-07-22 | GALT | Galectin Therapeutics Inc | Eldred Kary | Dir | P - Purchase | $2.39 | +400 | 54,138 | +1% | +$956 | |||||
2024-01-16 | GALT | Galectin Therapeutics Inc | Eldred Kary | Dir | P - Purchase | $2.39 | +400 | 54,138 | +1% | +$956 | ||||||
2024-07-22 | BSPK | Bespoke Extracts, Inc. | Feinsod Michael | CEO, 10% | P - Purchase | $0.07 | +3,000 | 2,148,112 | 0% | +$210 | ||||||
2024-07-19 | LQDA | Liquidia Corp | Saggar Rajeev | Chief Medical Officer | S - Sale | $11.13 | -1,873 | 208,329 | -1% | -$20,846 | ||||||
2024-07-18 | TNGX | Tango Therapeutics, Inc. | Third Rock Ventures Iv, L.P. | 10% | S - Sale | $9.81 | -191,490 | 18,459,814 | -1% | -$1,878,479 | ||||||
| M | 2024-07-18 | ACRS | Aclaris Therapeutics, Inc. | Leonard Braden Michael | 10% | P - Purchase | $1.30 | +154,722 | 27,180,977 | +1% | +$201,808 | |||||
2024-07-18 | GLSI | Greenwich Lifesciences, Inc. | Thompson Jaye | VP Clinical Reg Affairs | P - Purchase | $16.00 | +1,000 | 261,348 | 0% | +$16,000 | ||||||
| D | 2024-07-18 | ANAB | Anaptysbio, Inc | Lizzul Paul F. | Chief Medical Officer | S - Sale+OE | $35.00 | -1,500 | 11,618 | -11% | -$52,500 | |||||
2024-07-17 | WGS | Genedx Holdings Corp. | Opko Health, Inc. | 10% | S - Sale | $32.93 | -25,000 | 3,408,403 | -1% | -$823,188 | ||||||
2024-07-17 | SLRN | Acelyrin, Inc. | Becker Daniel J. | Dir | S - Sale | $6.86 | -1 | 2,999 | 0% | -$7 | ||||||
2024-07-17 | RENB | Renovaro Inc. | William Anderson Wittekind | 10% | S - Sale | $1.46 | -16,362 | 18,484,310 | 0% | -$23,889 | ||||||
2024-07-18 | ANIP | Ani Pharmaceuticals Inc | Shanmugam Muthusamy | HEAD OF R, D, COO-NOVITIUM OPS | S - Sale | $62.00 | -2,743 | 706,272 | 0% | -$170,066 | ||||||
| D | 2024-07-17 | ABBV | Abbvie Inc. | Gonzalez Richard A | Exec COB | S - Sale+OE | $175.00 | -282,845 | 513,099 | -36% | -$49,497,875 | |||||
| DM | 2024-07-17 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $332.74 | -7,200 | 646,231 | -1% | -$2,395,736 | |||||
| D | 2024-07-18 | PEPG | Pepgen Inc. | Mellion Michelle L | Chief Medical Officer | S - Sale+OE | $18.20 | -12,625 | 0 | -100% | -$229,804 | |||||
| M | 2024-07-17 | ELYM | Eliem Therapeutics, Inc. | Morisset Valerie | EVP, R, D, CSO | S - Sale | $6.93 | -41,783 | 160,523 | -21% | -$289,492 | |||||
2024-07-18 | BHVN | Biohaven Ltd. | Childs John W | Dir | P - Purchase | $35.67 | +28,400 | 6,460,644 | 0% | +$1,012,983 | ||||||
2024-07-17 | ESPR | Esperion Therapeutics, Inc. | Warren Eric | Chief Commercial Officer | S - Sale | $2.59 | -108 | 165,478 | 0% | -$279 | ||||||
2024-07-17 | ESPR | Esperion Therapeutics, Inc. | Foody Joanne M. | Chief Medical Officer | S - Sale | $2.60 | -917 | 272,862 | 0% | -$2,383 | ||||||
| D | 2024-07-16 | AKRO | Akero Therapeutics, Inc. | White William Richard | CFO | S - Sale+OE | $28.05 | -34,811 | 41,791 | -45% | -$976,274 | |||||
2024-07-17 | PBYI | Puma Biotechnology, Inc. | Nougues Maximo F | CFO | S - Sale | $3.70 | -4,156 | 162,522 | -2% | -$15,382 | ||||||
2024-07-17 | PBYI | Puma Biotechnology, Inc. | Ludwig Jeffrey Jerome | Chief Commercial Officer | S - Sale | $3.70 | -2,598 | 118,388 | -2% | -$9,615 | ||||||
2024-07-17 | PBYI | Puma Biotechnology, Inc. | Hunt Douglas M | See Remarks | S - Sale | $3.70 | -3,637 | 133,227 | -3% | -$13,461 | ||||||
2024-07-17 | PBYI | Puma Biotechnology, Inc. | Auerbach Alan H | Pres, CEO, 10% | S - Sale | $3.70 | -21,920 | 7,063,515 | 0% | -$81,128 | ||||||
| D | 2024-07-16 | MLYS | Mineralys Therapeutics, Inc. | Rodman David Malcom | Chief Medical Officer | S - Sale+OE | $15.00 | -525 | 102,873 | -1% | -$7,876 | |||||
| D | 2024-07-16 | RYTM | Rhythm Pharmaceuticals, Inc. | Shulman Joseph | Chief Technical Officer | S - Sale+OE | $53.00 | -10,468 | 30 | -100% | -$554,817 | |||||
2024-07-16 | EQ | Equillium, Inc. | Keyes Jason A | CFO | S - Sale | $0.87 | -10,000 | 141,633 | -7% | -$8,700 | ||||||
2024-07-16 | PTCT | Ptc Therapeutics, Inc. | Gravier Pierre | CFO | S - Sale | $34.02 | -2,269 | 53,531 | -4% | -$77,200 | ||||||
2024-07-16 | SPRY | Ars Pharmaceuticals, Inc. | Lowenthal Richard E | Pres, CEO, 10% | S - Sale | $11.40 | -100,000 | 12,365,600 | -1% | -$1,140,295 | ||||||
2024-07-16 | SPRY | Ars Pharmaceuticals, Inc. | Tanimoto Sarina | Chief Medical Officer, 10% | S - Sale | $11.40 | -100,000 | 12,365,600 | -1% | -$1,140,295 | ||||||
2024-07-17 | OPTN | Optinose, Inc. | Krick Anthony J | Chief Accounting Officer | S - Sale | $1.14 | -6,845 | 140,758 | -5% | -$7,803 | ||||||
2024-07-17 | OPTN | Optinose, Inc. | Marino Michael F III | GC, Corp Sec | S - Sale | $1.14 | -49,408 | 550,464 | -8% | -$56,325 | ||||||
2024-07-16 | NKTX | Nkarta, Inc. | Hager Alicia J. | GC | S - Sale | $8.00 | -3,396 | 103,819 | -3% | -$27,168 | ||||||
2024-07-17 | OPTN | Optinose, Inc. | Mahmoud Ramy A | CEO | S - Sale | $1.14 | -111,426 | 1,379,400 | -7% | -$127,026 | ||||||
2024-07-17 | TNGX | Tango Therapeutics, Inc. | Third Rock Ventures Iv, L.P. | 10% | S - Sale | $9.79 | -550,171 | 18,651,304 | -3% | -$5,386,339 | ||||||
2024-07-18 | MURA | Mural Oncology Plc | Keson-Brookes Maiken | See Remarks | S - Sale | $3.41 | -2,157 | 43,850 | -5% | -$7,355 | ||||||
2024-07-17 | ETST | Earth Science Tech, Inc. | Tabraue Mario Guillermo | COO | P - Purchase | $0.20 | +10,000 | 12,341,023 | 0% | +$2,000 | ||||||
| M | 2024-07-15 | TERN | Terns Pharmaceuticals, Inc. | Gordon Carl L | Dir, 10% | S - Sale | $10.00 | -56,164 | 755,635 | -7% | -$561,640 | |||||
| M | 2024-07-15 | TERN | Terns Pharmaceuticals, Inc. | Orbimed Advisors LLC | Dir, 10% | S - Sale | $10.00 | -56,164 | 755,635 | -7% | -$561,640 | |||||
| DM | 2024-07-15 | TERN | Terns Pharmaceuticals, Inc. | Quigley Jill M. | Dir | S - Sale+OE | $10.00 | -14,765 | 30,000 | -33% | -$147,660 | |||||
2024-07-16 | MNKD | Mannkind Corp | Binder Steven B. | EVP Special Projects | S - Sale | $5.93 | -2,836 | 1,100,860 | 0% | -$16,817 | ||||||
2024-07-16 | MNKD | Mannkind Corp | Thomson David | EVP Genl Counsel, Secretary | S - Sale | $5.93 | -3,115 | 857,885 | 0% | -$18,472 | ||||||
2024-07-15 | ELVN | Enliven Therapeutics, Inc. | Heyman Richard A. | Dir | S - Sale | $24.80 | -1,270 | 199,319 | -1% | -$31,497 | ||||||
| M | 2024-07-15 | ANIP | Ani Pharmaceuticals Inc | Shanmugam Muthusamy | HEAD OF R, D, COO-NOVITIUM OPS | S - Sale | $63.73 | -47,257 | 709,015 | -6% | -$3,011,592 | |||||
2024-07-16 | ELYM | Eliem Therapeutics, Inc. | Morisset Valerie | EVP, R, D, CSO | S - Sale | $7.13 | -50,000 | 202,306 | -20% | -$356,500 | ||||||
2024-07-15 | ARDX | Ardelyx, Inc. | Raab Michael | Pres, CEO | S - Sale | $5.97 | -7,500 | 1,285,827 | -1% | -$44,768 | ||||||
2024-07-17 | ZVRA | Zevra Therapeutics, Inc. | Clifton R. Laduane | CFO, Treasurer | P - Purchase | $6.77 | +2,000 | 18,469 | +12% | +$13,540 | ||||||
| D | 2024-07-15 | CRNX | Crinetics Pharmaceuticals, Inc. | Knight Jeff E. | COO | S - Sale+OE | $55.00 | -27,000 | 51,653 | -34% | -$1,485,000 | |||||
| D | 2024-07-15 | CRNX | Crinetics Pharmaceuticals, Inc. | Wilson Marc | CFO | S - Sale+OE | $55.00 | -25,000 | 111,092 | -18% | -$1,375,000 | |||||
| D | 2024-07-16 | IONS | Ionis Pharmaceuticals Inc | Klein Joseph III | Dir | S - Sale+OE | $50.00 | -12,000 | 16,446 | -42% | -$600,000 | |||||
| D | 2024-07-16 | IONS | Ionis Pharmaceuticals Inc | Diaz Allene M. | Dir | S - Sale+OE | $49.49 | -1,637 | 15,716 | -9% | -$81,019 | |||||
2024-07-16 | DAWN | Day One Biopharmaceuticals, Inc. | Blackman Samuel C. | HEAD OF R, D | S - Sale | $16.01 | -20,000 | 2,121,081 | -1% | -$320,226 | ||||||
2024-07-15 | ANNX | Annexon, Inc. | Overdorf Michael | EVP, CHIEF BUSINESS OFFICER | S - Sale | $6.02 | -784 | 94,622 | -1% | -$4,720 | ||||||
2024-07-15 | ANNX | Annexon, Inc. | Lew Jennifer | EVP, CFO | S - Sale | $6.03 | -1,104 | 86,468 | -1% | -$6,657 | ||||||
2024-07-15 | ANNX | Annexon, Inc. | Yednock Ted | EVP, CHIEF INNOVATION OFFICER | S - Sale | $6.02 | -1,106 | 92,365 | -1% | -$6,658 | ||||||
| D | 2024-07-15 | ANAB | Anaptysbio, Inc | Renton Hollings | Dir | S - Sale+OE | $30.64 | -10,000 | 1,950 | -84% | -$306,422 | |||||
2024-07-15 | RENB | Renovaro Inc. | William Anderson Wittekind | 10% | S - Sale | $1.41 | -21,954 | 18,518,672 | 0% | -$30,955 | ||||||
| DM | 2024-07-15 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $327.16 | -7,200 | 646,231 | -1% | -$2,355,544 | |||||
2024-07-15 | PHAT | Phathom Pharmaceuticals, Inc. | Nabulsi Azmi | COO | S - Sale | $11.72 | -10,901 | 1,029,700 | -1% | -$127,760 | ||||||
2024-07-15 | PHAT | Phathom Pharmaceuticals, Inc. | Henderson Molly | CFO, CBO | S - Sale | $11.72 | -4,325 | 101,358 | -4% | -$50,689 | ||||||
2024-07-15 | PHAT | Phathom Pharmaceuticals, Inc. | Curran Terrie | Pres, Chief Exec | S - Sale | $11.72 | -33,848 | 381,574 | -8% | -$396,699 | ||||||
| M | 2024-07-02 | BIOE | Bio Essence Corp | Yan Yin | CEO, 10% | S - Sale | $8.03 | -60,274 | 18,939,726 | 0% | -$484,286 | |||||
| D | 2024-07-15 | CDMO | Avid Bioservices, Inc. | Richieri Richard A. | Chief Operations Officer | S - Sale+OE | $8.36 | -530 | 41,186 | -1% | -$4,431 | |||||
| D | 2024-07-15 | CDMO | Avid Bioservices, Inc. | Kwietniak Matthew R. | Chief Commercial Officer | S - Sale+OE | $8.36 | -307 | 23,410 | -1% | -$2,567 | |||||
| M | 2024-07-12 | ELYM | Eliem Therapeutics, Inc. | Morisset Valerie | EVP, R, D, CSO | S - Sale | $7.04 | -92,377 | 252,306 | -27% | -$650,563 | |||||
| M | 2024-07-12 | ELVN | Enliven Therapeutics, Inc. | Patel Anish | COO | S - Sale | $25.06 | -50,000 | 344,027 | -13% | -$1,252,826 | |||||
| D | 2024-07-12 | ELVN | Enliven Therapeutics, Inc. | Hohl Benjamin | CFO | S - Sale+OE | $25.07 | -3,000 | 0 | -100% | -$75,195 | |||||
| D | 2024-07-15 | CYTK | Cytokinetics Inc | Parshall B Lynne | Dir | S - Sale+OE | $55.82 | -5,000 | 20,600 | -20% | -$279,100 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |